Curaleaf Responds To FDA Warning Letter

Earlier this week, the Food and Drug Administration (FDA) issued a warning letter to Massachusetts-based, multi-state cannabis operator Curaleaf Holdings, Inc. to advise the company that some of the marketing for cannabidiol (CBD) products on its website and social media pages was in violation of the Food, Drug, and Cosmetic (FD&C) Act and FDA regulations

Curaleaf responded to the FDA on Thursday, informing the agency that the issues presented in the letter had been addressed.

Upon receipt of the FDA warning letter, Curaleaf Hemp performed a full review of its website and social media platforms to remove non-compliant statements and claims about the company’s products.

The company also removed the Curaleaf Hemp blog and took down all third party links in it.

According to Curaleaf, some of the products that were listed in the FDA warning letter had been previously discontinued.

“We care deeply about our customers and making a difference in our industry,” said Curaleaf CEO Joseph Lusardi in a statement. “Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve.”

Lusardi says that the industry needs, wants, and appreciates the work that the FDA is doing to ensure regulation and compliance in the CBD marketplace.